share_log

Evome Medical Technologies Reviews Highlights of Low-CapEx Revenue Growth Plan

Evome Medical Technologies Reviews Highlights of Low-CapEx Revenue Growth Plan

Evome醫療技術回顧了低資本支出營業收入增長計劃的亮點
GlobeNewswire ·  08/15 19:30

Posts updated corporate presentation to website

更新了企業介紹文稿到網站

Reminder: Conference call to be held on August 19th to discuss Q2 2024 financial results

提醒:8月19日將舉行電話會議,討論2024年第二季度財務業績

SHIRLEY, N.Y., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the "Company" or "Evome") (TSXV: EVMT) highlights its low-CapEx plan for growing revenue in an updated corporate presentation now available at .

紐約州Shirley,2024年8月15日(全球新聞發佈)- Evome Medical Technologies Inc.(以下簡稱「公司」或「Evome」)(TSXV:EVMT)在最新的企業介紹文稿中強調了其低資本支出計劃以增加營業收入。詳細內容請查看

The presentation, to be used during investor meetings planned for next month in New York, Vancouver, Montreal, and Toronto, highlights recent progress to stabilize the business and generate consistent positive Adjusted EBITDA1, as well as a fresh growth strategy based on leveraging the Biodex brand of its core business, Biodex Medical Systems, Inc. ("Biodex"), and its more than 15,000 customers served over the past 30 years. The revenue strategy features expanding the product portfolio with the addition of novel products, largely sourced from single-product companies that are privately owned and undercapitalized, and are suffering from limited distribution, both domestically and internationally.

該介紹文稿將在下個月在紐約,溫哥華,蒙特利爾和多倫多的投資者會議中使用,重點介紹了穩定業務和產生持續積極調整後的息稅折舊和攤銷前利潤(Adjusted EBITDA1)的最新進展,以及基於利用其核心業務Biodex Medical Systems, Inc.(「Biodex」)及其過去30年服務的超過15,000名客戶進行的全新增長策略。該營收策略重點擴大產品組合,通過增加來自單一產品公司的新產品來實現,這些公司屬於私人所有並資本化不足,並因受到國內外限制分銷的影響而遭受困境。

Growth Plan Highlights

成長計劃亮點

  • Focus on Core Expertise: Prioritize clinical devices, therapeutic modalities and digital applications that complement Biodex's strengths in orthopedic, neurologic and cardiopulmonary rehabilitation.
  • Global Distribution Network: Utilize Biodex's extensive network of 52 distributors reaching more than 70 countries to maximize market reach and penetration.
  • Brand Leverage: Capitalize on the Biodex brand, widely recognized as a leader in isokinetic physical therapy, to drive brand trust and product sales.
  • Strategic Acquisitions: Aim to acquire or license one new product per quarter, beginning in Q4 of this year.
  • 專注核心專業知識:優先考慮臨床設備、治療模式和數字應用,以補充Biodex在矯形、神經學和心肺康復方面的優勢。
  • 全球分銷網絡:利用Biodex的51名經銷商分佈在70多個國家,以最大限度地擴大市場覆蓋面和滲透率。
  • 品牌槓桿效應:利用Biodex品牌的知名度,將其視爲同濟大學等物理治療方面的領導者,以推動品牌信任和產品銷售。
  • 戰略收購:旨在從今年第四季度開始,每季度收購或授權一個新產品。

"The Biodex brand and its large customer database are the keys to our success and future growth," said Mike Seckler, CEO. "Our customers demand new and novel devices and services, and they trust our brand and value their long-standing relationships with us. As such, we are well-positioned to make other products available to expand their clinical offering and keep them competitive. At the same time, there are hundreds of small, private companies who are selling a single product with limited U.S. distribution and no international reach. By acquiring or licensing these products, we can brand them as Biodex and make them available to our customers worldwide."

首席執行官邁克·西克勒(Mike Seckler)說:「Biodex品牌和其龐大的客戶數據庫是我們成功和未來增長的關鍵。我們的客戶需要新的新穎設備和服務,他們信任我們的品牌並重視他們與我們的長期關係。因此,我們有條件使其他產品可用以擴大他們的臨床服務,並使他們更具競爭力。同時,有成百上千的小型私人公司在銷售單一產品,且美國分銷和國際擴展有限。通過收購或獲得這些產品的許可,我們可以將它們打造成Biodex品牌,並將它們提供給我們的全球客戶。」

"From a financial perspective, our plan is based on using very limited capital thereby reducing our need for debt or equity financing to grow revenue," he added. "Our plan is to leverage existing relationships and invest in sales and marketing, rather than pursue capital-intensive product development."

他補充說:「從財務角度來看,我們的計劃基於使用非常有限的資本,從而減少了增加營收的債務或股票融資的需求。我們的計劃是利用現有的關係並投資於銷售和市場營銷,而不是追求資本密集型產品開發。」

Prior to joining Evome, Mr. Seckler served as VP of Global Marketing at Ferring Pharmaceuticals, a multibillion-dollar company, where he led revenue growth and international distribution and was responsible for evaluating potential mergers, acquisitions and business development initiatives.

米爾·Seckler先生在加入Evome之前曾擔任Ferring藥業公司全球營銷副總裁,該公司是一家數十億美元的公司,他帶領營收增長和國際分銷,並負責評估潛在的併購、收購和業務發展倡議。

Conference Call

電話會議

As a reminder, the Company will hold a conference call on Monday, August 19, 2024, at 2:00 PM Eastern time (11:00 AM Pacific time). The call will be hosted by Mike Seckler, CEO, and Gordon Bean, CFO. Please register via the link below to attend.

提醒:公司將於2024年8月19日星期一美國東部時間下午2:00(太平洋時間上午11:00)召開電話會議。該會議由首席執行官Mike Seckler和首席財務官Gordon Bean主持。請通過下面的鏈接註冊參加。

Date: Monday, August 19, 2024
Time: 2:00 PM Eastern time (11:00 AM Pacific time)
Link for attendees to register:

日期:2024年8月19日星期一
時間:美國東部時間下午2:00(美國太平洋時間上午11:00)
與會者註冊鏈接:

About Evome

關於Evome

Evome Medical Technologies Inc. (TSXV: EVMT) specializes in human performance and rehabilitative solutions achieved through strategic acquisitions and leveraging the intellectual properties of specialized companies under its wholly-owned subsidiaries. Evome's goal is to create a large, broad-based medical device company with global reach. For more information visit .

Evome Medical Technologies Incorporated(TSXV:EVMT)專注於通過戰略收購和利用其全資子公司的專業公司的知識產權實現人類表現和恢復性解決方案。Evome的目標是創建一個具有全球影響力的大型廣泛醫療設備公司。欲了解更多信息,請訪問。

Biodex is a leader in innovative rehabilitation solutions, recognized for its advanced product line serving orthopedic, sports medicine and neurorehabilitation needs. Renowned for its precision and durability, Biodex offers advanced equipment such as balance and mobility systems, isokinetic testing devices and comprehensive upper extremity rehabilitation tools. With a presence in over 70 countries and partnerships with 52 distributors, Biodex continues to drive advancements in patient care through a strong commitment to research, education and technology integration.

Biodex是創新康復解決方案的領導者,以其先進的產品線服務於矯形、運動醫學和神經康復需求而聞名。Biodex以其精度和耐久性而著稱,提供先進的設備,如平衡和移動系統、等速肌力測試設備以及全面的上肢康復工具。Biodex在70多個國家擁有分支機構,並與52名經銷商合作,通過堅定不移地致力於研究、教育和技術整合,不斷推動患者護理的進步。

For Additional Information:

其他信息:

Mike Seckler ‎
Chief Executive Officer
info@evomemedical.com‎

Mike Seckler
首席執行官
info@evomemedical.com

For Media and Investor Relations:

媒體和投資關係:

irlabs
Alyssa Barry
Principal and Co-Founder
1 (833) 947-5227

irlabs
Alyssa Barry
負責人和聯合創始人
1(833)947-5227

Additional Information

附加信息

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the ‎policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this ‎release.‎

TSX Venture Exchange及其監管服務提供商(以下稱爲TSX Venture Exchange政策定義的那個術語)對本發佈內容的充分性或準確性不承擔任何責任。

There can be no assurance that any acquisitions (including the proposed acquisitions disclosed herein) ‎will be completed or the sale price or timing of any acquisition. Completion of any transaction will be ‎subject to, amongst other things, negotiation and execution of definitive agreements, and applicable ‎director, shareholder and regulatory approvals.‎

無法保證任何收購(包括此處披露的建議收購)將完成或任何收購的銷售價格或時間。任何交易完成均需經過協商和達成書面協議,並獲得適用的董事、股東和監管批准,且還可能受其他標準條件限制。

Certain statements contained in this press release constitute "forward-looking information" within the meaning of applicable Canadian securities laws. These statements can be identified by the use of forward-looking terminology such as "expects" "believes", "estimates", "may", "would", "could", ‎‎"should", "potential", ‎‎‎‎‎"will", "seek", "intend", "plan", and "anticipate", and similar expressions as they relate ‎‎‎‎to the Company, including the entirety of the Company's growth plan and its potential results. All ‎statements ‎other than statements of ‎historical fact may be forward-looking‎ information. Such statements reflect the Company's current views and intentions with respect to future ‎events, and current information available to the Company, and are subject to certain risks, ‎uncertainties and assumptions, including: the Company successfully identifying sellers and negotiating and closing transactions in an effort to acquire or license products at a certain pace per quarter. The Company cautions that the forward-looking statements contained herein are qualified by important factors that could cause actual results to differ materially from those reflected by such statements. Such factors include but are not limited to the ‎‎general business and ‎‎economic ‎conditions in the regions in ‎which the Company operates; the ability of the Company to execute on key ‎‎priorities, ‎including the successful completion of acquisitions, business‎ retention, and‎‎ strategic plans and to‎‎ attract, develop ‎and retain key executives; difficulty integrating newly acquired businesses; ‎‎ongoing or new disruptions in the supply chain, the extent and scope of such supply chain disruptions, and the timing or extent of the resolution or improvement of such disruptions; the ability to‎‎‎ implement business strategies and pursue business opportunities; ‎‎disruptions in or attacks (including ‎cyber-attacks) on the Company's information technology, internet, network access or other ‎‎voice or data ‎communications systems or services; the evolution of various types of fraud or other ‎‎‎criminal behavior to which ‎ the Company is exposed; the failure of third parties to comply with their obligations to ‎‎ the Company or its ‎affiliates; the‎ impact of new and changes to, or application of, current laws and regulations; ‎granting of permits and licenses in a highly regulated business; the ‎overall difficult ‎‎‎‎‎litigation environment, including in the United States; increased competition; changes in foreign currency rates; ‎increased ‎‎‎‎funding ‎costs and market volatility due to market illiquidity and competition for funding; the ‎availability of funds ‎‎‎‎and resources to pursue operations; critical ‎accounting estimates and changes to accounting standards, policies,‎‎‎‎ and methods used by the Company; the occurrence of natural and unnatural‎‎ catastrophic ‎events ‎and claims ‎‎‎‎resulting from such events; as well as those risk factors discussed or ‎referred to ‎in the ‎Company's disclosure ‎documents filed with United States Securities and Exchange Commission ‎and ‎available at ‎www.sec.gov, and with ‎the securities regulatory authorities in certain provinces of Canada and ‎‎available at ‎. Should any ‎factor affect the Company in an unexpected manner, or should ‎‎assumptions underlying ‎the forward-looking ‎information prove incorrect, the actual results or events may differ ‎‎materially from the results ‎or events predicted. ‎Any such forward-looking information is expressly qualified in its ‎‎entirety by this cautionary ‎statement. Moreover, ‎the Company does not assume responsibility for the accuracy or ‎‎completeness of such ‎forward-looking ‎information. The forward-looking information included in this press release ‎‎is made as of the ‎date of this press ‎release and the Company undertakes no obligation to publicly update or revise ‎‎any forward-‎looking information, ‎other than as required by applicable law‎.

本新聞稿中包含的某些陳述構成適用加拿大證券法的「前瞻性信息」。這些陳述可通過使用前瞻性術語,如「預計」、「相信」、「估計」、「可能」、「可以」、「應該」、「潛在」、「將」、「尋求」、「打算」和「預見」等類似表達,與公司相關聯,包括公司整個增長計劃及其潛在結果。除歷史事實陳述外,所有陳述均可能是前瞻性信息。此類陳述反映了公司對未來事件的當前看法和意圖,以及公司可獲得的當前信息,並受到某些風險、不確定性和假設的影響,包括:公司成功確定賣家並談判和關閉交易,以便每季度以一定速度收購或許可產品。公司提醒,本新聞稿中包含的前瞻性陳述受到重要因素的限制,這些因素可能導致實際結果與此類陳述反映的結果有實質性不同。此類因素包括但不限於公司所在地區的一般商業和經濟條件;公司能否執行關鍵重點任務,包括成功完成收購、業務保留和戰略計劃並吸引、發展和保留關鍵高管;難以整合新獲得的業務;供應鏈上的持續或新的中斷,此類供應鏈中斷的程度和範圍,以及這些中斷的解決或改善的時間或程度;實施業務戰略和追求業務機會的能力;對公司的信息技術、互聯網、網絡訪問或其他語音或數據通信系統或服務進行干擾或攻擊(包括網絡攻擊)的形式的演變;各種詐騙類型或其他公司所面臨的犯罪行爲的發生;第三方未履行對公司或其附屬公司的義務的影響;新法律和法規的頒佈和變更或應用的影響;在高度管制的行業中授予許可證和執照;總體不良訴訟環境,包括在美國;競爭加劇;匯率變動;由於市場流動性不足和融資競爭增加而產生的增加的資金成本和市場波動性;獲得資金和資源以推進業務的可用性;公司使用的關鍵會計估計及會計標準、政策和方法的更改;自然和人爲災害事件的發生及其產生的索賠;以及所討論或涉及的風險因素在美國證券交易委員會提交的披露文件中討論或涉及,並可在www.sec.gov上獲得,在加拿大某些省份的證券監管機構處獲得。如果任何因素以意外的方式影響公司,或者假設支撐前瞻性信息證明不正確,則實際結果或事件可能與預測的結果或事件實質性不同。任何此類前瞻性信息均由本警示聲明完全有條件地合格。此外,公司不承擔對此類前瞻性信息的準確性或完整性的責任。本新聞稿中包含的前瞻性信息截至本新聞稿發佈日期,公司不承擔公開更新或修訂任何前瞻性信息的義務,除非適用法律要求。

This press release refers to "Adjusted EBITDA" which is a non-GAAP and non-IFRS financial ‎measure ‎that does ‎not have a standardized meaning prescribed by GAAP or IFRS. The ‎Company's presentation ‎of this financial ‎measure may not be comparable to similarly titled ‎measures used by other ‎companies. This non-GAAP financial measure assists the Company's ‎management in comparing its ‎operating performance over time because certain items may ‎obscure underlying business trends and ‎make comparisons of long-term performance difficult, ‎as they are of a nature and/or size that occur ‎with inconsistent frequency or relate to discrete ‎acquisition plans that are fundamentally different ‎from the ongoing operating plans of the ‎Company. The Company's management also believes that ‎presenting this measure allows ‎investors to view the Company's performance using the same ‎measures that the Company ‎uses in evaluating its financial and business performance and trends.‎ "Adjusted EBITDA" is defined as net loss excluding interest expense, provision for income ‎taxes, ‎depreciation of property and equipment, amortization of right-of-use asset, amortization ‎of intangible ‎asset, foreign exchange (loss) gain, other income, provision for impairment, ‎change in fair value of ‎contingent consideration, transaction costs, gain/loss on sale of business and stock-based ‎‎compensation.‎

本新聞稿提到的「調整後的EBITDA」是一項非GAAP和非IFRS財務指標,不具有GAAP或IFRS規定的標準意義。公司介紹的這個財務衡量標準可能與其他公司使用的同類指標不可比較。此非GAAP財務指標可幫助公司管理層比較公司的經營績效,因爲某些項目可能會掩蓋基本業務趨勢,使得長期績效的比較困難,因爲這些項目的性質和/或規模具有不一致的頻率或與基本的不同收購計劃直接相關的性質。公司管理層還認爲,提供此衡量標準允許投資者使用與公司用於評估其財務和業務績效及趨勢的相同衡量標準來看待公司的績效。 「調整後的EBITDA」定義爲淨虧損,不包括利息支出,所得稅賠付,固定資產折舊,經營租賃固定資產攤銷,無形資產攤銷,匯兌(損失)收益,其他收入,計提減值,應計負債的公允價值變動,交易成本,出售業務的收益/損失和股票補償。

1 Non-GAAP financial measure or ratio. See "Additional Information" below.‎

1. 非GAAP財務指標或比率,請參見下文「其他信息」。


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論